2017 Fiscal Year Final Research Report
The chemoprevention of esophageal carcinogenesis with chronic inflammation by the suppression of lipoxygenase
| Project/Area Number |
15K10090
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
伏田 幸夫 金沢大学, 医学系, 准教授 (10301194)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 食道発癌 / 炎症発癌 / ラットモデル / LOX |
|---|
| Outline of Final Research Achievements |
The incidence of Barrett’s epithelium in control group was 94%, in pranlukast group; 69%, the incidence of esophageal adenocarcinoma in control group; 69%, pranlukast group; 15%. Both of Barrett’s epithelium and esophageal adenocarcinoma generation were significantly suppressed by pranlukast administration. Pranlukast administration suppressed tissue growth activity and increased apoptosis. Infiltrating macrophages were reduced by pranlukast administration.
The administration of pranlukast suppressed the generation of Barrett's epithelium and· esophageal adenocarcinoma. Suppression of chronic inflammatory condition by LOX inhibition lead to suppression of carcinogenesis. Moreover, infiltration of macrophages was particularly suppressed among inflammatory cells. Excessive stimulation of tissue growth by macrophages was considered to be one of carcinogenic factors.
|
| Free Research Field |
消化器外科学
|
